WO2015095834A3 - Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2 - Google Patents

Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2 Download PDF

Info

Publication number
WO2015095834A3
WO2015095834A3 PCT/US2014/071736 US2014071736W WO2015095834A3 WO 2015095834 A3 WO2015095834 A3 WO 2015095834A3 US 2014071736 W US2014071736 W US 2014071736W WO 2015095834 A3 WO2015095834 A3 WO 2015095834A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
subject
erk1
bcl
effects
Prior art date
Application number
PCT/US2014/071736
Other languages
English (en)
Other versions
WO2015095834A2 (fr
Inventor
Saurabh Saha
Dean WELSCH
Gary Decrescenzo
Jeffrey James ROIX
Original Assignee
Biomed Valley Discoveries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries, Inc. filed Critical Biomed Valley Discoveries, Inc.
Publication of WO2015095834A2 publication Critical patent/WO2015095834A2/fr
Publication of WO2015095834A3 publication Critical patent/WO2015095834A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

La présente invention concerne, inter alia, des méthodes pour le traitement ou l'amélioration des effets d'un cancer chez un sujet qui a besoin d'un tel traitement. Ces méthodes consistent à administrer au sujet une quantité efficace de (i) un inhibiteur de l'ERK1/2 (tel que le BVD-523) ou son sel pharmaceutiquement acceptable, et (ii) un inhibiteur de la famille BCL-2 (tel que le navitoclax) ou son sel pharmaceutiquement acceptable, pour traiter ou améliorer les effets du cancer. L'invention concerne également des kits et des compositions pharmaceutiques pour le traitement ou l'amélioration des effets d'un cancer chez un sujet et des méthodes permettant de sélectionner un sujet atteint d'un cancer qui pourrait bénéficier d'une pharmacothérapie comprenant une association médicamenteuse.
PCT/US2014/071736 2013-12-20 2014-12-19 Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2 WO2015095834A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919148P 2013-12-20 2013-12-20
US61/919,148 2013-12-20

Publications (2)

Publication Number Publication Date
WO2015095834A2 WO2015095834A2 (fr) 2015-06-25
WO2015095834A3 true WO2015095834A3 (fr) 2015-08-27

Family

ID=53403900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/071736 WO2015095834A2 (fr) 2013-12-20 2014-12-19 Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2

Country Status (1)

Country Link
WO (1) WO2015095834A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7427212B2 (ja) 2013-12-20 2024-02-05 バイオメッド バレー ディスカバリーズ，インコーポレイティド 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2015160975A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
JP2018528206A (ja) * 2015-08-28 2018-09-27 ノバルティス アーゲー Ｍｄｍ２阻害剤およびその組み合わせ物
KR20180096621A (ko) * 2015-12-18 2018-08-29 이그니타, 인코포레이티드 암의 치료용 조합물
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
CN115279375A (zh) 2019-11-05 2022-11-01 艾伯维公司 用于以navitoclax治疗骨髓纤维化和mpn相关病症的给药方案
IT201900023895A1 (it) * 2019-12-13 2021-06-13 Univ Degli Studi Padova Combinazione comprendente il composto bh3-mimetico abt-199 (venetoclax) e almeno un inibitore della produzione di nadph e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b, preferibilmente nel trattamento del linfoma diffuso a grandi cellule b (dlbcl)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAIN ET AL.: "Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.", CLIN CANCER RES., vol. 20, no. 2, 31 October 2013 (2013-10-31), pages 490 - 498, XP055221318 *
MELCHER ET AL.: "Spectral karyotyping of the human colon cancer cell lines SW480 and SW620.", CYTOGENET CELL GENET., vol. 88, no. 1-2, 2000, pages 145 - 52 *
MORRIS ET AL.: "Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.", C ANCER DISCOV., vol. 3, no. 7, July 2013 (2013-07-01), pages 742 - 50, XP055219076 *
SALE ET AL.: "That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.", BR J PHARMACOL., vol. 169, no. 8, August 2013 (2013-08-01), pages 1708 - 1722, XP055221313 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7427212B2 (ja) 2013-12-20 2024-02-05 バイオメッド バレー ディスカバリーズ，インコーポレイティド 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物

Also Published As

Publication number Publication date
WO2015095834A2 (fr) 2015-06-25

Similar Documents

Publication Publication Date Title
WO2015095834A3 (fr) Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2
WO2015095819A3 (fr) Traitement du cancer faisant appel à des associations d'inhibiteurs de l'erk et de la raf
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EP4241850A3 (fr) Inhibiteurs de mdm2 et combinaisons de ceux-ci
MX2016007351A (es) Terapia de combinacion para tratar cancer.
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
WO2016133903A3 (fr) Polythérapie pour le traitement du cancer
EP4140487A8 (fr) Polythérapie anticancéreuse
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
IN2015DN00376A (fr)
SG10201902664RA (en) Combination therapy for treating cancer
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
PH12016502352A1 (en) Pharmaceutical composition
PH12016502353A1 (en) Pharmaceutical composition
WO2015095838A3 (fr) Traitements du cancer faisant appel à des associations d'inhibiteurs de l'erk et de la mek de type 1
MX2014011270A (es) Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r.
WO2015035410A8 (fr) Traitement du cancer
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2016106357A8 (fr) Combinaison d'inhibiteurs de raf et d'inhibiteurs de kinases aurora
WO2017037578A3 (fr) Polythérapie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14872812

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14872812

Country of ref document: EP

Kind code of ref document: A2